BeOne Medicines Ltd.

ISIN US07725L1026

 | 

WKN A1437N

Marktkapitalisatie (in EUR)
33,144 m
Land
Switzerland
Sector
Healthcare
Dividendrendement
0.00%
 

Overzicht

Beschrijving

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Toon meer Toon minder
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Switzerland

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 33,144 m
WPA, EUR 2.24
KBV 7.9
K/W 122.6
Dividendrendement 0.00%

Income statement (2025)

Omzet, EUR 4,749 m
Netto-inkomen, EUR 255 m
Winstmarge 5.37%

What ETF is BeOne Medicines Ltd. in?

There is 1 ETF which contains BeOne Medicines Ltd..
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.76%
Equity
United States
Health Care
Biotech
48
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.

Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.